These findings suggest that WT1 directed immunotherapies, ESK1 [36], or with bi-specific T cell-engaging antibodies (BiTEs) [81] or anti-WT1 T cells [82] or CAR T cells [83,84] may have therapeutic potential in KS. This evidence concerns the gene WT1 and Kaposi's sarcoma.